Product
CTX130
2 clinical trials
1 abstract
2 indications
Indication
T-Cell LymphomaIndication
Renal Cell CarcinomaClinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2027-03-01
Clinical trial
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell DifferentiationStatus: Active (not recruiting), Estimated PCD: 2027-02-01